Companies Myriad Genetics Inc
Myriad Genetics (MYGN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Myriad Genetics Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Say-on-pay support95.04%Latest vote
CEO vs. named peers15th pct.Of 21 peer CEOs
CEO pay, last three years
- $5,686,740FY2025
CEO total pay was $5,686,740 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $856,901 · bonus $0 · stock awards $3,989,729 · option awards $0
Executives and directors
Brian Donnelly · CCOBenjamin Wheeler · CFODale Muzzey · Chief Scientific OfficerMargaret Ancona · ExecutiveMark Verratti · COOPaul Diaz · ExecutiveSamraat Raha · CEOScott Leffler · CFOColleen F. Reitan · Independent DirectorDaniel M. Skovronsky · Independent DirectorHeiner Dreismann · Independent DirectorLee N. Newcomer · Independent DirectorMark S. Davis · Independent DirectorPaul M. Bisaro · Independent DirectorRashmi Kumar · Independent DirectorS. Louise Phanstiel · Chair of the Board
Frequently asked questions
Who was the highest-paid executive at Myriad Genetics Inc in fiscal 2025?
As disclosed, Brian Donnelly (Chief Commercial Officer) was the highest-paid executive at Myriad Genetics Inc in fiscal 2025, with total compensation of $6,000,145.
How does Myriad Genetics Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Samraat Raha's total compensation ranked at the 15th percentile of Myriad Genetics Inc's disclosed peer group.
What is Myriad Genetics Inc's CEO-to-median employee pay ratio?
Myriad Genetics Inc's CEO-to-median employee pay ratio is temporarily unavailable.
How did shareholders vote on Myriad Genetics Inc's executive compensation?
As disclosed, 95.04% of shareholders supported Myriad Genetics Inc's executive compensation in the latest say-on-pay vote.
How much does Myriad Genetics Inc spend in total on board compensation for fiscal 2025?
As disclosed, Myriad Genetics Inc reported total board compensation of $2,674,155 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Brian Donnelly | $350,000 | $450,000 | $4,801,898 | $0 | $371,910 | $0 | $26,337 | $6,000,145 |
| Chief Commercial Officer | ||||||||
| Samraat Raha | 856,901 | 0 | 3,989,729 | 0 | 814,660 | 0 | 25,450 | 5,686,740 |
| President and Chief Executive Officer | ||||||||
| Mark Verratti | 622,883 | 0 | 2,058,069 | 0 | 438,323 | 0 | 25,976 | 3,145,251 |
| Chief Operating Officer | ||||||||
| Scott Leffler | 393,798 | 0 | 1,067,674 | 0 | 0 | 0 | 1,275,021 | 2,736,493 |
| Former Chief Financial Officer | ||||||||
| Margaret Ancona | 330,850 | 0 | 800,754 | 0 | 0 | 0 | 763,561 | 1,895,166 |
| Former EVP, Strategy and Transformation | ||||||||
| Dale Muzzey | 506,400 | 0 | 1,121,054 | 0 | 221,677 | 0 | 13,781 | 1,862,912 |
| Chief Scientific Officer | ||||||||
| Benjamin Wheeler | 408,493 | 0 | 759,229 | 0 | 325,421 | 0 | 14,754 | 1,507,897 |
| Chief Financial Officer | ||||||||
| Paul Diaz | 418,103 | 0 | 0 | 0 | 0 | 0 | 270,534 | 688,637 |
| Former President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Brian Donnelly | $6,000,145 | — | — | — |
| Samraat Raha | 5,686,740 | — | — | — |
| Mark Verratti | 3,145,251 | — | — | — |
| Scott Leffler | 2,736,493 | — | — | — |
| Margaret Ancona | 1,895,166 | — | — | — |
| Dale Muzzey | 1,862,912 | — | — | — |
| Benjamin Wheeler | 1,507,897 | — | — | — |
| Paul Diaz | 688,637 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation program is designed to support our mission and business strategy, with the primary objectives of attracting and retaining executive talent, motivating our executive officers through pay-for-performance metrics to enhance our growth and profitability, and increasing long-term stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Margaret Ancona | PSU | 2025-06-05 | 40,592 | 54,123 | — | 81,185 | $275,751 |
| Benjamin Wheeler | PSU | 2025-06-05 | 3,000 | 4,000 | — | 6,000 | 20,379 |
| Dale Muzzey | RSU | 2025-03-13 | — | — | 75,773 | — | 734,998 |
| Scott Leffler | PSU | 2025-06-05 | 54,124 | 72,165 | — | 108,248 | 367,673 |
| Samraat Raha | PSU | 2025-06-05 | 162,371 | 216,495 | — | 324,743 | 1,103,020 |
| Dale Muzzey | PSU | 2025-06-05 | 56,830 | 75,773 | — | 113,660 | 386,056 |
| Mark Verratti | PSU | 2025-06-05 | 74,420 | 99,227 | — | 148,841 | 505,551 |
| Brian Donnelly | PSU | 2025-06-05 | 95,722 | 127,629 | — | 191,444 | 650,258 |
| Benjamin Wheeler | PSU | 2025-08-16 | 45,000 | 60,000 | — | 90,000 | 357,450 |
| Samraat Raha | RSU | 2025-03-13 | — | — | 216,495 | — | 2,100,002 |
| Samraat Raha | PSU | 2025-04-30 | — | 141,050 | — | — | 786,707 |
| Brian Donnelly | PSU | 2025-05-01 | — | 236,167 | — | — | 1,317,222 |
| Mark Verratti | PSU | 2025-04-30 | — | 105,785 | — | — | 590,016 |
| Scott Leffler | RSU | 2025-03-13 | — | — | 72,165 | — | 700,001 |
| Mark Verratti | RSU | 2025-03-13 | — | — | 99,227 | — | 962,502 |
| Brian Donnelly | RSU | 2025-05-01 | — | — | 269,905 | — | 1,924,423 |
| Benjamin Wheeler | RSU | 2025-03-13 | — | — | 4,000 | — | 38,800 |
| Benjamin Wheeler | RSU | 2025-08-16 | — | — | 60,000 | — | 342,600 |
| Margaret Ancona | RSU | 2025-03-13 | — | — | 54,124 | — | 525,003 |
| Brian Donnelly | RSU | 2025-05-01 | — | — | 127,629 | — | 909,995 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Margaret Ancona | $525,003 | $275,751 | $0 | 34.4% |
| Benjamin Wheeler | 381,400 | 377,829 | 0 | 49.8% |
| Dale Muzzey | 734,998 | 386,056 | 0 | 34.4% |
| Scott Leffler | 700,001 | 367,673 | 0 | 34.4% |
| Samraat Raha | 2,100,002 | 1,889,727 | 0 | 47.4% |
| Mark Verratti | 962,502 | 1,095,567 | 0 | 53.2% |
| Brian Donnelly | 2,834,418 | 1,967,480 | 0 | 41.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dale Muzzey | RSU | 750 | — | $4,613 |
| Benjamin Wheeler | RSU | 1,250 | — | 7,688 |
| Dale Muzzey | RSU | 1,875 | — | 11,531 |
| Benjamin Wheeler | RSU | 1,999 | — | 12,294 |
| Benjamin Wheeler | RSU | 2,500 | — | 15,375 |
| Mark Verratti | RSU | 2,500 | — | 15,375 |
| Benjamin Wheeler | RSU | 3,333 | — | 20,498 |
| Benjamin Wheeler | RSU | 4,000 | — | 24,600 |
| Dale Muzzey | RSU | 4,004 | — | 24,625 |
| Mark Verratti | RSU | 4,809 | — | 29,575 |
| Benjamin Wheeler | RSU | 5,000 | — | 30,750 |
| Benjamin Wheeler | RSU | 6,000 | — | 36,900 |
| Benjamin Wheeler | RSU | 7,500 | — | 46,125 |
| Dale Muzzey | RSU | 9,486 | — | 58,339 |
| Mark Verratti | RSU | 13,134 | — | 80,774 |
| Margaret Ancona | RSU | 16,418 | — | 100,971 |
| Dale Muzzey | RSU | 28,459 | — | 175,023 |
| Dale Muzzey | RSU | 32,833 | — | 201,923 |
| Margaret Ancona | RSU | 35,178 | — | 216,345 |
| Mark Verratti | RSU | 39,087 | — | 240,385 |
| Mark Verratti | RSU | 39,404 | — | 242,335 |
| Samraat Raha | RSU | 42,996 | — | 264,425 |
| Paul Diaz | RSU | 43,286 | — | 266,209 |
| Scott Leffler | RSU | 46,904 | — | 288,460 |
| Dale Muzzey | RSU | 49,249 | — | 302,881 |
| Mark Verratti | RSU | 58,630 | — | 360,575 |
| Benjamin Wheeler | RSU | 60,000 | — | 369,000 |
| Samraat Raha | RSU | 64,493 | — | 396,632 |
| Paul Diaz | RSU | 65,674 | — | 403,895 |
| Dale Muzzey | RSU | 75,773 | — | 466,004 |
| Mark Verratti | RSU | 99,227 | — | 610,246 |
| Mark Verratti | RSU | 105,785 | — | 650,578 |
| Samraat Raha | RSU | 118,180 | — | 726,807 |
| Brian Donnelly | RSU | 127,629 | — | 784,918 |
| Paul Diaz | Option | 135,636 | 13.38 | — |
| Samraat Raha | RSU | 141,050 | — | 867,458 |
| Paul Diaz | RSU | 164,165 | — | 1,009,615 |
| Paul Diaz | RSU | 197,023 | — | 1,211,691 |
| Samraat Raha | RSU | 216,495 | — | 1,331,444 |
| Brian Donnelly | RSU | 236,167 | — | 1,452,427 |
| Paul Diaz | RSU | 246,247 | — | 1,514,419 |
| Brian Donnelly | RSU | 269,905 | — | 1,659,916 |
| Paul Diaz | Option | 342,040 | 13.38 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| S. Louise PhanstielIndependent · Board Chair · Audit · Public Company Governance · Audit and Finance · Board Diversity · Finance and Accounting · Leadership · Healthcare Industry · Provider or Payer Perspective | $206,000 | $244,996 | — | — | — | $450,996 |
| Lee N. NewcomerIndependent · Compensation · Research and Product Innovation (Chair) · Leadership · Healthcare Industry · Diagnostic Industry · Research and Development · Provider or Payer Perspective · Public Company Governance | 98,000 | 244,996 | — | — | — | 342,996 |
| Heiner DreismannIndependent · Compensation (Chair) · Research and Product Innovation · Leadership · Healthcare Industry · Diagnostic Industry · Research and Development · Public Company Governance | 93,500 | 244,996 | — | — | — | 338,496 |
| Colleen F. ReitanIndependent · Audit · Public Company Governance · Audit and Finance · Board Diversity · Finance and Accounting · Leadership · Healthcare Industry · Provider or Payer Perspective · Technology | 93,500 | 244,996 | — | — | — | 338,496 |
| Paul M. BisaroIndependent · Compensation · Research and Product Innovation · Finance and Accounting · Leadership · Healthcare Industry · Diagnostic Industry · Public Company Governance | 89,251 | 244,996 | — | — | — | 334,247 |
| Daniel M. SkovronskyIndependent · Compensation · Research and Product Innovation · Leadership · Healthcare Industry · Diagnostic Industry · Research and Development | 83,500 | 244,996 | — | — | — | 328,496 |
| Rashmi KumarIndependent · Audit · Public Company Governance · Audit and Finance · Board Diversity · Leadership · Healthcare Industry · Technology | 83,500 | 244,996 | — | — | — | 328,496 |
| Mark S. DavisIndependent · Audit (Chair) · Public Company Governance · Audit and Finance · Finance and Accounting · Leadership · Healthcare Industry | 93,124 | 118,808 | — | — | — | 211,932 |
| Samraat S. RahaEmployee director · Board Diversity · Finance and Accounting · Leadership · Healthcare Industry · Diagnostic Industry · Research and Development | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $350,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 28,000 / 20,000 / 20,000 |
| Stock ownership guideline | As of December 31, 2025, all of our directors and executive officers were in compliance with the stock ownership requirements or have additional time to meet the applicable stock ownership requirements within the five-year period to achieve compliance. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $840,375 |
| Equity awards (grant-date value) | $1,833,780 |
| All other compensation | $0 |
| Total cost of the board | $2,674,155 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Myriad Genetics as a peer
Companies that benchmark against MYGN
14 companies name MYGN as a compensation peer
The list of companies that name MYGN as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CHRS Coherus BioSciences, Inc.EXEL Exelixis Inc.DVAX Dynavax Technologies CorporationVNDA Vanda Pharmaceuticals Inc.ACAD ACADIA Pharmaceuticals Inc.BMRN BioMarin Pharmaceutical Inc.EXAS Exact Sciences CorporationGH Guardant Health, Inc.IONS Ionis Pharmaceuticals, Inc.IRWD Ironwood Pharmaceuticals, Inc.NEO Neogenomics, Inc.ALKS Alkermes plcNBIX Neurocrine Biosciences Inc.NTRA Natera, Inc.TECH Bio-Techne CorporationVCYT Veracyte, Inc.INCY Incyte CorporationPTCT PTC Therapeutics, Inc.SRPT Sarepta Therapeutics, Inc.UTHR United Therapeutics Corporation Adjusted EPS
Peer reciprocity
The companies Myriad Genetics Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 4 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 5 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 6 | Exact Sciences Corporation | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 7 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 8 | Neurocrine Biosciences Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 9 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 10 | Neogenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 11 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 12 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 13 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 14 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 15 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 16 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 17 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 18 | Myriad Genetics Inc | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 19 | Vanda Pharmaceuticals Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 20 | Coherus BioSciences, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 21 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Myriad Genetics Inc | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Coherus BioSciences, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Exelixis Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 · Option 35 | No | Aon |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Neogenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Neurocrine Biosciences Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Vanda Pharmaceuticals Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 59,356,710 | 3,098,966 | 47,644 | 95.04% | Passed |
| 2025 | 2025-06-05 | 67,755,156 | 5,847,659 | 80,243 | 92.06% | Passed |
| 2024 | 2024-06-06 | 74,410,679 | 4,060,490 | 54,013 | 94.83% | Passed |
| 2023 | 2023-06-01 | 68,121,537 | 2,731,973 | 36,771 | 96.09% | Passed |
| 2022 | 2022-06-02 | 67,116,767 | 3,590,907 | 29,702 | 94.92% | Passed |
| 2021 | 2021-06-03 | 62,380,220 | 1,697,829 | 33,215 | 97.35% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dale Muzzey | Chief Scientific Officer | 2026-04-14 | D | 946 | $5 | $4,645 | Common | Form 4 ↗ |
| Mark Verratti | Chief Operating Officer | 2026-04-14 | D | 1,069 | 5 | 5,249 | Common | Form 4 ↗ |
| Brian Donnelly | Chief Commerical Officer | 2026-05-01 | D | 55,975 | 5 | 268,680 | Common | Form 4 ↗ |
| Paul M. Bisaro | Director | 2026-05-14 | A | 7,500 | 4 | 27,638 | Common | Form 4 ↗ |
| Raj Jampa | Chief Technology Officer | 2026-06-01 | A | 251,889 | 0 | 0 | Common | Form 4 ↗ |
| Rashmi Kumar | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| Paul M. Bisaro | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| Lee N. Newcomer | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| Colleen F. Reitan | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| Heiner Dreismann | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| S. Louise Phanstiel | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| Mark S. Davis | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| Daniel M. Skovronsky | Director | 2026-06-04 | A | 59,701 | 0 | 0 | Common | Form 4 ↗ |
| Rashmi Kumar | Director | 2026-06-08 | D | 15,000 | 4 | 66,843 | Common | Form 4 ↗ |
| Brian Donnelly | Chief Commerical Officer | 2026-06-11 | A | 5,000 | 4 | 19,680 | Common | Form 4 ↗ |
| Samraat S. Raha | Director | 2026-06-11 | A | 3,542 | 4 | 13,941 | Common | Form 4 ↗ |
| Benjamin Wheeler | Chief Financial Officer | 2026-08-16 | D | 8,761 | 3 | 26,546 | Common | Form 4 ↗ |
| Jennifer Lynne Fox | Chief Legal Officer | 2026-09-03 | D | 4,398 | 3 | 14,206 | Common | Form 4 ↗ |
| Vishal Sikri | EVP, Commercial | 2026-09-16 | A | 257,731 | 0 | 0 | Common | Form 4 ↗ |
| Benjamin Wheeler | Chief Financial Officer | 2026-09-21 | D | 2,555 | 4 | 10,246 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (83 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Brian Donnelly. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 6,000,145. View filing ↗
- Section 01, Samraat Raha. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 5,686,740. View filing ↗
- Section 01, Mark Verratti. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 3,145,251. View filing ↗
- Section 01, Scott Leffler. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 2,736,493. View filing ↗
- Section 01, Margaret Ancona. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 1,895,166. View filing ↗
- Section 01, Dale Muzzey. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 1,862,912. View filing ↗
- Section 01, Benjamin Wheeler. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 1,507,897. View filing ↗
- Section 01, Paul Diaz. DEF 14A, filed 2026-04-14. Section “Summary Compensation Table” · page 50. As printed: 688,637. View filing ↗
- Section 03, Margaret Ancona PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Benjamin Wheeler PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Dale Muzzey RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Leffler PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Samraat Raha PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Dale Muzzey PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Verratti PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Donnelly PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Benjamin Wheeler PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Samraat Raha RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Samraat Raha PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Donnelly PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Verratti PSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Leffler RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Verratti RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Donnelly RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Benjamin Wheeler RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Benjamin Wheeler RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Margaret Ancona RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Donnelly RSU. DEF 14A, filed 2026-04-14. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 08, S. Louise Phanstiel. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 450,996. View filing ↗
- Section 08, Lee N. Newcomer. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 342,996. View filing ↗
- Section 08, Heiner Dreismann. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 338,496. View filing ↗
- Section 08, Colleen F. Reitan. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 338,496. View filing ↗
- Section 08, Paul M. Bisaro. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 334,247. View filing ↗
- Section 08, Daniel M. Skovronsky. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 328,496. View filing ↗
- Section 08, Rashmi Kumar. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 328,496. View filing ↗
- Section 08, Mark S. Davis. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 211,932. View filing ↗
- Section 08, Samraat S. Raha. DEF 14A, filed 2026-04-14. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Dale Muzzey 2026-04-14. Form 4, filed 2026-04-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Verratti 2026-04-14. Form 4, filed 2026-04-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Donnelly 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul M. Bisaro 2026-05-14. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Jampa 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rashmi Kumar 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul M. Bisaro 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lee N. Newcomer 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Colleen F. Reitan 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heiner Dreismann 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, S. Louise Phanstiel 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark S. Davis 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel M. Skovronsky 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rashmi Kumar 2026-06-08. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Donnelly 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Samraat S. Raha 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Wheeler 2026-08-16. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Lynne Fox 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vishal Sikri 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Wheeler 2026-09-21. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 840,375 + equity 1,833,780 + all other 0 = 2,674,155, summed across the director compensation table rows.
- Exelixis Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- PTC Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. View filing ↗
- BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
- United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
- Exact Sciences Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. View filing ↗
- Natera, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. View filing ↗
- Neurocrine Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
- Neogenomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Neogenomics, Inc.'s own proxy. As printed: 9,127,092. View filing ↗
- Guardant Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Dynavax Technologies Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. View filing ↗
- Bio-Techne Corporation, Section 10b CEO total. DEF 14A, filed 2025-09-19. CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. View filing ↗
- Alkermes plc, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. View filing ↗
- Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
- Veracyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. View filing ↗
- Myriad Genetics Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Myriad Genetics Inc's own proxy. As printed: 5,686,740. View filing ↗
- Vanda Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals Inc.'s own proxy. As printed: 3,851,468. View filing ↗
- Coherus BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences, Inc.'s own proxy. As printed: 2,736,874. View filing ↗
- Ironwood Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. View filing ↗
- Section 10a, Neogenomics, Inc. reciprocity. DEF 14A. Neogenomics, Inc. names Myriad Genetics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Veracyte, Inc. reciprocity. DEF 14A. Veracyte, Inc. names Myriad Genetics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, United Therapeutics Corporation reciprocity. DEF 14A. United Therapeutics Corporation names Myriad Genetics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗